Delving into the Latest Updates on HIV vaccine Vacc-4x(Bionor Immuno AS) with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine

Synonyms

HIV vaccine Vacc-4x, Kick, VACC 4X

+ [1]

Target-

Mechanism

Immunostimulants, T lymphocytes stimulants

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication

HIV Infections

Inactive Indication-

Originator Organization

Bionor Immuno AS

Active Organization

Celgene Corp.Eurocine Vaccines AB

Inactive Organization

Bionor Immuno AS

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

The REDUC trial's objective is to address one of the core issues with the treatment of HIV, which is that some HIV infected cells hide in so-called latent reservoirs. The reservoirs are unaffected by conventional HIV medication and invisible to the immune system. HDACi have the potential to activate these latently infected cells. This will make the HIV infected cells visible to the immune system; the immune response generate by Vacc-4x will be able to attack and eliminate the infected cells.

Start Date01 Mar 2014

Sponsor / Collaborator

Bionor Immuno AS

[+1]

EUCTR2012-002281-12-DE / Not yet recruitingNot Applicable

Re-boosting of Subjects Previously Included in the CT BI-Vacc-4x 2007/1 Study. An Open, Multicenter, Immunogenicity, Follow-up Reboosting Study with Vacc-4x in Subjects Infected with HIV-1 Who Have Maintained an Adequate Response to ART

Start Date01 Feb 2013

Sponsor / Collaborator

Bionor Immuno AS

100 Clinical Results associated with HIV vaccine Vacc-4x(Bionor Immuno AS)

Login to view more data

100 Translational Medicine associated with HIV vaccine Vacc-4x(Bionor Immuno AS)

Login to view more data

100 Patents (Medical) associated with HIV vaccine Vacc-4x(Bionor Immuno AS)

Login to view more data

23

Literatures (Medical) associated with HIV vaccine Vacc-4x(Bionor Immuno AS)

27 Nov 2019·Journal of medicinal chemistryQ1 · MEDICINE

Sugar Kick Prevents Memory Impairment

Q1 · MEDICINE

Article

Author: Rudrawar, Santosh ; Ryan, Philip

Pathological hyperphosphorylation of tau and subsequent aggregation to form neurofibrillary tangles (NFTs) is closely related to progression of neurodegenerative diseases such as Alzheimer's disease (AD) and progressive supranuclear palsy. A recent study showed that MK-8719 (6) is a selective and potent small molecule inhibitor of human O-GlcNAcase (hOGA). The pharmacological inhibition of OGA, the sole enzyme involved in removal of a sugar moiety (O-GlcNAc residue) from tau, increases global O-GlcNAc levels within the brain and reduces tau phosphorylation. The OGA inhibitor slows neurodegeneration and improves cognitive function in AD and related tauopathies. Here, we discuss the findings of that study and the development of OGA inhibitors as novel therapeutic strategy for treatment of age-related memory impairment in neurodegenerative diseases.

01 Mar 2019·AIDS (London, England)

Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals

Article

Author: Kim, Peggy ; Tolstrup, Martin ; Moron-Lopez, Sara ; Søgaard, Ole S ; Yukl, Steven A ; Wong, Joseph K

OBJECTIVES:

Reversing HIV-1 latency has been suggested as a strategy to eradicate HIV-1. We investigated the effect of romidepsin on the HIV transcription profile in participants from the REDUC part B clinical trial.

DESIGN:

Seventeen participants on suppressive antiretroviral therapy were vaccinated with six doses of the therapeutic vaccine Vacc-4x followed by treatment with three doses of romidepsin. Samples from nine study participants were available for HIV transcription profile analysis.

METHODS:

Read-through, total (TAR), elongated (longLTR), polyadenylated (polyA) and multiply-spliced (Tat-Rev) HIV transcripts and total HIV DNA were quantified at baseline (visit 1) and 4 h after the second (visit 10b) and third (visit 11b) romidepsin infusions.

RESULTS:

Read-through, total, elongated, and polyadenylated HIV transcripts increased after romidepsin infusion (P = 0.020, P = 0.0078, P = 0.0039, P = 0.027, respectively), but no changes were observed in multiply-spliced HIV RNA or HIV DNA. No change was observed in the ratio of read-through/total HIV transcripts. The ratio of elongated/total HIV RNA increased after romidepsin (P = 0.016), whereas the ratio of polyadenylated/elongated HIV decreased. Both elongated HIV transcripts and total HIV DNA correlated negatively with the time to viral rebound after interruption of ART.

CONCLUSIONS:

In these patients, romidepsin increased early events in HIV transcription (initiation and especially elongation), but had less effect on later stages (completion, multiple splicing) that may be required for comprehensive latency reversal and cell killing. Without cell death, increased HIV transcription before or after latency reversal may hasten viral rebound after therapy interruption.

13 Nov 2018·AIDS (London, England)Q2 · MEDICINE

Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals

Q2 · MEDICINE

Article

100 Deals associated with HIV vaccine Vacc-4x(Bionor Immuno AS)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 2	US	Bionor Immuno AS	01 Aug 2008
HIV Infections	Phase 2	DE	Bionor Immuno AS	01 Aug 2008
HIV Infections	Phase 2	IT	Bionor Immuno AS	01 Aug 2008
HIV Infections	Phase 2	ES	Bionor Immuno AS	01 Aug 2008
HIV Infections	Phase 2	GB	Bionor Immuno AS	01 Aug 2008

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01704781 (IMID, CTgov)	Phase 1/2	HIV Infections	36	Lenalidomide+Vacc-4X+rhuGM-CSF (Part B: Lenalidomide)	wkpvcdtwhk(hnulafvosd) = mbthggjmoo bhwglhjpsm (bwpyescosi, ruzzrpxxxv - zwtmaxwysk) View more	-	08 Mar 2017
				Lenalidomide placebo+Vacc-4X+rhuGM-CSF (Part B: Lenalidomide Placebo)	wkpvcdtwhk(hnulafvosd) = jaubdgubvt bhwglhjpsm (bwpyescosi, tzewmqzjbt - mvqzecirln) View more
NCT01712256 (Re-boost \| 2012/1, CTgov)	Phase 2	HIV Infections	33	Vacc-4x	bliljtgqhr(xueglbkjds) = txqrmugadg ajbslwovhq (vjolahbdvy, eoynqnqjzu - sfdiiociip) View more	-	06 Mar 2017
NCT02092116 (REDUC, CTgov)	Phase 1/2	HIV Infections	26	Romidepsin (Part A)	glyhlkzkoc(rnubhtocgn) = zfvfogxkqy eiiliceqgg (vtfbodeilq, nhxfojzmex - quwpmzqoog) View more	-	01 Mar 2017
				rhuGM-CSF+Vacc-4x+Romidepsin (Part B)	qxrvhlerpz(xhxmtgwvop) = swefvalvpp grexgbogbp (dgkbjqahkn, sawdchcpnd - xzkajtcocv) View more
NCT00659789 (CTgov)	Phase 2	HIV Infections	137	GM-CSF+Vacc-4x (Vacc-4x Immunization (Adjuvant: GM-CSF) (Group I) While on ART)	idpsyskasw(vyrhvsmyvq) = jikhikonht rmfjcmhsgx (ytulwpvhfc, aypcjrlden - xlpxbylesk) View more	-	05 Jan 2017
				Placebo (Placebo Injections (Group II) While on ART.)	idpsyskasw(vyrhvsmyvq) = awctnfqcmx rmfjcmhsgx (ytulwpvhfc, fmfeobmpwb - rytwoopxjj) View more
NCT00659789 (Pubmed \| Lancet Infect Dis) Manual	Phase 2	HIV Infections	136	Vacc 4x	tekyspobvw(msuaecuhhd) = hpnkhwjpbv wrgwrpvrgf (dnqzyevwle ) View more	Negative	01 Apr 2014
				Placebo	tekyspobvw(msuaecuhhd) = dtazjijorq wrgwrpvrgf (dnqzyevwle ) View more
NCT00659789 (IAS2011)	Phase 2	HIV Infections	135	Vacc-4x	mmebnvdvoa(sewjgtzola) = nbzqmbyzqg tjxeeynnpo (jepzzsdryo )	Positive	01 Jan 2011
				Placebo	mmebnvdvoa(sewjgtzola) = qlxpxvrnyv tjxeeynnpo (jepzzsdryo )